Renal Cell Carcinoma

First-line lenvatinib and pembrolizumab showed similar overall survival rates and improved progression-free survival and response rates vs global standard-of-care immunotherapies among patients with advanced renal cell carcinoma.

Patients with advanced/metastatic clear cell renal cell carcinoma who received belzutifan took longer to experience worsening symptoms and reported higher quality-of-life scores on questionnaires.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the case of an older patient with metastatic renal cell carcinoma who had recurrent disease after receiving axitinib and pembrolizumb, then single-agent cabozantinib. This is the first of 2 articles based on this event.

In this Q&A discussion, Hans Hammers, MD, PhD, explains the rationale for continued use of tyrosine kinase inhibitor and PD-L1 therapy combinations, like lenvatinib and pembrolizumab, for patients with advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, discussed his approach to recognizing and managing adverse events related to treatment with cabozantinib and nivolumab in patients with advanced renal cell carcinoma. This is the second article based on this event.

Pembrolizumab plus cabozantinib showed promising activity with an objective response rate of 65.8%, median progression-free survival of 10.45 months, and median overall survival of 30.81 months in metastatic renal cell carcinoma.

The landmark study, KEYNOTE-564, compared pembrolizumab vs placebo in patients with clear cell renal cell carcinoma who were at high risk for recurrence after nephrectomy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, examined the significance of the 44-month follow-up of the CheckMate 9ER trial of patients with metastatic renal cell carcinoma.

Though the combination of talazoparib and avelumab was safe as a treatment for patients with specific types of kidney cancer, the combination was not effective, according to findings from a phase 2 trial.

Belzutifan is now an FDA-approved treatment for adult patients with advanced renal cell carcinoma.

In separate live events, Yasser Mohamed Ali Ged, MBBS, and Deepak Kilari, MD, discussed the best treatment options for patients with advanced renal cell carcinoma and what role tyrosine kinase inhibitors play for these patients.

Clinical trials are shedding light into best treatment approaches for non–clear cell renal cell carcinoma, including immunotherapy plus tyrosine kinase inhibitor combinations, as discussed in Case-Based Roundtable events.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Chandler Park, MD, reviewed the latest updates of the pivotal trials of frontline combination therapies for advanced clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.

Early trials are exploring the benefit of chimeric antigen receptor T-cell therapy in advanced renal cell carcinoma.

In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.

The RCC Cancer Immunity Cycle may inform the treatment and development of novel therapies in renal cell carcinoma moving forward.

An expert discussed how the use of circulating tumor DNA in patients with RCC may help guide whether treatment should be intensified or deescalated.

Alan Tan, MD, discusses areas of interest in the research and development of circulating tumor DNA in renal cell carcinoma.

Results unveiled at the 2023 International Kidney Cancer Symposium revealed that patients with advanced clear cell renal cell carcinoma in the 200-mg dose group achieved an overall response rate of 23.1% based on blinded independent central review.

In a presentation at the 2023 International Kidney Cancer Symposium, Jaleh Fallah, MD, discussed the regulatory agency’s evaluation of data from the phase 2 LITESPARK-004 trial, which led to the approval of belzutifan.

Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.

An expert discussed how recent studies in patients with translocation RCC, a rare type of RCC, have demonstrated that the disease responds well to immune checkpoint inhibitors, but more focus is needed on novel targets to treat it.

The combination of SRK-181 and pembrolizumab demonstrated improvements in objective response rate among patients with clear cell renal cell carcinoma in a phase 1 proof-of-concept study.